How to buy Arrowhead Pharmaceuticals stock - 13 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Arrowhead Pharmaceuticals stock

Own Arrowhead Pharmaceuticals stock in just a few minutes.

Arrowhead Pharmaceuticals, Inc is a biotechnology business based in the US. Arrowhead Pharmaceuticals shares (ARWR) are listed on the NASDAQ and all prices are listed in US Dollars. Arrowhead Pharmaceuticals employs 232 staff and has a trailing 12-month revenue of around USD$79.8 million.

How to buy shares in Arrowhead Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Arrowhead Pharmaceuticals. Find the stock by name or ticker symbol: ARWR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Arrowhead Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Arrowhead Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Arrowhead Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Arrowhead Pharmaceuticals share price

Use our graph to track the performance of ARWR stocks over time.

Arrowhead Pharmaceuticals shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$30.83 - USD$92.6
50-day moving average USD$72.5177
200-day moving average USD$68.893
Wall St. target priceUSD$91.17
PE ratio 478.5556
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.092

Buy Arrowhead Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arrowhead Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Arrowhead Pharmaceuticals under- or over-valued?

Valuing Arrowhead Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arrowhead Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Arrowhead Pharmaceuticals's P/E ratio

Arrowhead Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 479x. In other words, Arrowhead Pharmaceuticals shares trade at around 479x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Arrowhead Pharmaceuticals's EBITDA

Arrowhead Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$5.9 million.

The EBITDA is a measure of a Arrowhead Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Arrowhead Pharmaceuticals financials

Revenue TTM USD$79.8 million
Gross profit TTM USD$88 million
Return on assets TTM -12.92%
Return on equity TTM -21.51%
Profit margin -128.52%
Book value $4.404
Market capitalisation USD$6.7 billion

TTM: trailing 12 months

Shorting Arrowhead Pharmaceuticals shares

There are currently 5.1 million Arrowhead Pharmaceuticals shares held short by investors – that's known as Arrowhead Pharmaceuticals's "short interest". This figure is 0.2% down from 5.1 million last month.

There are a few different ways that this level of interest in shorting Arrowhead Pharmaceuticals shares can be evaluated.

Arrowhead Pharmaceuticals's "short interest ratio" (SIR)

Arrowhead Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Arrowhead Pharmaceuticals shares currently shorted divided by the average quantity of Arrowhead Pharmaceuticals shares traded daily (recently around 886270.1208981). Arrowhead Pharmaceuticals's SIR currently stands at 5.79. In other words for every 100,000 Arrowhead Pharmaceuticals shares traded daily on the market, roughly 5790 shares are currently held short.

However Arrowhead Pharmaceuticals's short interest can also be evaluated against the total number of Arrowhead Pharmaceuticals shares, or, against the total number of tradable Arrowhead Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arrowhead Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Arrowhead Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0579% of the tradable shares (for every 100,000 tradable Arrowhead Pharmaceuticals shares, roughly 58 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arrowhead Pharmaceuticals.

Find out more about how you can short Arrowhead Pharmaceuticals stock.

Arrowhead Pharmaceuticals share dividends

We're not expecting Arrowhead Pharmaceuticals to pay a dividend over the next 12 months.

Have Arrowhead Pharmaceuticals's shares ever split?

Arrowhead Pharmaceuticals's shares were split on a 1:10 basis on 16 November 2011. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arrowhead Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arrowhead Pharmaceuticals shares which in turn could have impacted Arrowhead Pharmaceuticals's share price.

Arrowhead Pharmaceuticals share price volatility

Over the last 12 months, Arrowhead Pharmaceuticals's shares have ranged in value from as little as $30.83 up to $92.6. A popular way to gauge a stock's volatility is its "beta".

ARWR.US volatility(beta: 1.27)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arrowhead Pharmaceuticals's is 1.267. This would suggest that Arrowhead Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Arrowhead Pharmaceuticals overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site